CIK 0001885522 · Non-accelerated filer<br>Smaller reporting company
Neumora Therapeutics, Inc.
Sign in to watch- Ticker
- NMRA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 844367680
- Phone
- (857) 760-0900
- Business address
- 260 ARSENAL PLACE, SUITE 1, WATERTOWN, MA, 02472
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $481,506
- in 2 filings
Net −$481,506. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-08 | Pinto Joshua President | Grant or award · Stock Option (Right to Buy) | +1,200,000 | 1,200,000 | ||
| 2026-01-08 | BERNS PAUL L See Remarks | Grant or award · Stock Option (Right to Buy) | +1,650,000 | 1,650,000 | ||
| 2025-11-11 | Aurora Daljit Singh See Remarks | Sale 10b5-1 | −114,703 | $2.68 | $307K | 0 |
| 2025-10-27 | Burow Kristina Director | Purchase | +1,915,700 | $2.61 | $5.0M | 6,046,907 |
| 2025-10-27 | ARCH Venture Partners XII, LLC 10% owner | Purchase | +1,915,700 | $2.61 | $5.0M | 6,046,907 |
| 2025-10-27 | ARCH Venture Partners X, LLC 10% owner | Purchase | +1,915,700 | $2.61 | $5.0M | 6,046,907 |
| 2025-05-28 | Milligan Michael Lee See Remarks | Returned to the company · Stock Option (Right to Buy) | −85,391 | 0 | ||
| 2025-05-28 | Milligan Michael Lee See Remarks | Returned to the company · Stock Option (Right to Buy) | −38,234 | 0 | ||
| 2025-05-28 | Milligan Michael Lee See Remarks | Returned to the company · Stock Option (Right to Buy) | −28,675 | 0 | ||
| 2025-05-28 | Milligan Michael Lee See Remarks | Returned to the company · Stock Option (Right to Buy) | −41,250 | 0 | ||
| 2025-05-28 | Milligan Michael Lee See Remarks | Returned to the company · Stock Option (Right to Buy) | −400,000 | 0 | ||
| 2025-05-28 | Milligan Michael Lee See Remarks | Grant or award · Stock Option (Right to Buy) | +85,391 | 85,391 | ||
| 2025-05-28 | Milligan Michael Lee See Remarks | Grant or award · Stock Option (Right to Buy) | +38,234 | 38,234 | ||
| 2025-05-28 | Milligan Michael Lee See Remarks | Grant or award · Stock Option (Right to Buy) | +28,675 | 28,675 | ||
| 2025-05-28 | Milligan Michael Lee See Remarks | Grant or award · Stock Option (Right to Buy) | +41,250 | 41,250 | ||
| 2025-05-28 | Milligan Michael Lee See Remarks | Grant or award · Stock Option (Right to Buy) | +400,000 | 400,000 | ||
| 2025-05-28 | Fust Matthew K Director | Returned to the company · Stock Option (Right to Buy) | −85,586 | 0 | ||
| 2025-05-28 | Fust Matthew K Director | Returned to the company · Stock Option (Right to Buy) | −27,802 | 0 | ||
| 2025-05-28 | Fust Matthew K Director | Returned to the company · Stock Option (Right to Buy) | −28,571 | 0 | ||
| 2025-05-28 | Fust Matthew K Director | Grant or award · Stock Option (Right to Buy) | +85,586 | 85,586 |
Page 4 of 20 · 384 trades